ash highlights: adding daratumumab to soc improves outcomes in multiple myeloma
Published 4 years ago • 116 plays • Length 7:27Download video MP4
Download video MP3
Similar videos
-
3:15
patient reported outcomes supports addition of daratumumab in multiple myeloma treatment
-
6:12
ash 2018: using daratumumab early with standard myeloma combos for newly diagnosed patients
-
7:32
long-term efficacy of daratumumab-based regimen in multiple myeloma
-
5:30
daratumumab plus standard treatment improves outcomes in relapsed, hard-to-treat multiple myeloma
-
7:06
phase i study shows daratumumab plus standard myeloma therapy improves outcomes in myeloma
-
1:15:59
february 25, 2022 | yale ash 2021highlights: multiple myeloma
-
5:03
daratumumab pomalidomide & dexamethasone effective in relapsed/refractory multiple myeloma
-
58:48
best of ash 2019
-
4:57
ash 2022: talquetamab showing promise in multiple myeloma clinical trial
-
1:16
rationale for adding daratumumab to rvd in multiple myeloma
-
16:34
ash 2016: multiple myeloma highlights
-
14:45
ash 2020 - highlights in myeloma
-
7:21
multiple myeloma highlights from ash 2019
-
3:44
ash 2021: new bispecific antibody, talquetamab, to treat multiple myeloma
-
1:00:50
best of ash 2021 webinar
-
1:56
highlights from ash 2019 for transplant eligible patients with ndmm
-
15:24
ash 2014: highlights in multiple myeloma
-
3:36
updates on daratumumab use in myeloma at ash 2020
-
14:28
all about darzalex (daratumumab) #myeloma